Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of KB304, a Replication-Defective, Non-Integrating Vector Expressing Human Type III Collagen (COL3) and Tropoelastin for the Treatment of Wrinkles

Next Previous
Trial Profile

A Phase 1/2 Study of KB304, a Replication-Defective, Non-Integrating Vector Expressing Human Type III Collagen (COL3) and Tropoelastin for the Treatment of Wrinkles

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs JN 304 (Primary) ; Sodium chloride
  • Indications Skin wrinkles
  • Focus Therapeutic Use
  • Acronyms Pearl-2
  • Sponsors Krystal Biotech

Most Recent Events

  • 17 Feb 2026 According to a Krystal Biotech media release, company expects to now initiate a Phase 2 study of its lead program, KB304, in 2027.
  • 04 Aug 2025 According to a Krystal Biotech media release, the Jeune company is planning to submit scale to US FDA that will align to the study protocol in 2nd half of 2025. Also, enable a potential Phase 2 study start in first half of 2026.
  • 24 Jul 2025 According to a Jeune media release, the company will be meeting with the FDA in the coming months to submit the decollete-specific photonumeric scale (JDWS) developed and validated by Jeune to the FDA and align on the Phase 2 study protocol in the 2H 2025 with the goal of initiating the Phase 2 study in the 1H 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top